← FDA DRUG APPROVALS

FDA ANDA · ANDA206623

BUDESONIDE

Sponsor: DR REDDYS LABS SA

APPLICATION
ANDA206623
TYPE
ANDA
ORIGINAL APPROVAL
2016-04-08
LATEST ACTION
2023-05-25
ROUTE
ORAL
DOSAGE FORM
CAPSULE, DELAYED RELEASE
MARKETING STATUS
Prescription

Products

BUDESONIDEPrescription
BUDESONIDE 3MG · CAPSULE, DELAYED RELEASE · ORAL

Approval history

2023-05-25Manufacturing (CMC) · Supplement 9 · standardAP
2023-05-25Labeling · Supplement 3 · standardAP
2023-05-25Labeling · Supplement 4 · standardAP
2016-04-08UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →